SCHEMBL23705295

SCHEMBL23705295

CC(C)S(=O)(=O)c1cccc(C(=O)NCC(=O)Nc2nc(-c3cccc(C#N)c3)cs2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR139 Q6DWJ6 1/20 0.49
▸ CSNK2A2 P19784 1/20 0.47
▸ CSNK2B P67870 1/20 0.47
▸ CSNK2A1 P68400 1/20 0.47
▸ CSNK2A3 Q8NEV1 1/20 0.47
▸ MAPT P10636 4/20 0.44
▸ ALDH1A1 P00352 4/20 0.44
▸ LMNA P02545 3/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ HPGD P15428 2/20 0.44
▸ ROCK2 O75116 1/20 0.44
▸ KDM4A O75164 2/20 0.43
▸ KDM4B O94953 2/20 0.43
▸ KDM5B Q9UGL1 2/20 0.43
▸ USP2 O75604 2/20 0.43
▸ PKM P14618 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ KDM5C P41229 1/20 0.43
▸ KAT6A Q92794 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23714804 0.98 GPR139 (0.47) GPR139CSNK2A2CSNK2BCSNK2A1CSNK2A3
SCHEMBL23714825 0.94 MAPT (0.43) GPR139CSNK2A2CSNK2BCSNK2A1CSNK2A3
SCHEMBL23704933 0.93 MAPT (0.48) GPR139MAPTALDH1A1LMNASMN1; SMN2
SCHEMBL25187645 0.92 GPR139 (0.44) GPR139CSNK2A2CSNK2BCSNK2A1CSNK2A3
SCHEMBL25179667 0.90 CSNK2A2 (0.41) GPR139CSNK2A2CSNK2BCSNK2A1CSNK2A3
SCHEMBL23705408 0.90 MAPT (0.45) GPR139MAPTALDH1A1LMNASMN1; SMN2
SCHEMBL30061722 0.89 MAPT (0.49) MAPTALDH1A1LMNASMN1; SMN2HPGD
SCHEMBL23704901 0.89 MAPT (0.49) MAPTALDH1A1LMNASMN1; SMN2HPGD
SCHEMBL21241898 0.89 MAPT (0.55) MAPTALDH1A1LMNASMN1; SMN2HPGD
SCHEMBL21224241 0.89 MEN1 (0.49) GPR139CSNK2A2CSNK2BCSNK2A1CSNK2A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 — — US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 — — US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 — — US disclosed
CN-115484948-A Compound and use thereof 福宏治疗公司 2022-12-16 — — CN disclosed
EP-4096657-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 — — EP disclosed
WO-2021155316-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149414-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB GPR139 4225/4885CSNK2A2 716/4885CSNK2B 868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback